therapeutics and clinical risk management

dovepress
open access to scientific and medical research

review

therapeutics and clinical risk management downloaded from https://www.dovepress.com/ by 185.250.42.216 on 10-aug-2018
for personal use only.

open access full text article

treatment of allergic rhinitis and urticaria: a review
of the newest antihistamine drug  xxxd338xxx 
this article was published in the following dove press journal:
therapeutics and clinical risk management
13 april 2016
number of times this article has been viewed

xue yan wang 1
margaret lim-jurado 2
narayanan prepageran 3
pongsakorn tantilipikorn 4
de yun wang 5
department of allergy, beijing
shijitan hospital, capital medical
university, beijing, people‚Äôs republic
of china; 2st luke‚Äôs medical center,
quezon city, manila, philippines;
3
department of otorhinolaryngology,
head & neck surgery, university
malaya faculty of medicine, kuala
lumpur, malaysia; 4rhinology and
allergy division, department of
otorhinolaryngology, faculty of
medicine siriraj hospital, mahidol
university, bangkok, thailand;
5
department of otolaryngology, yong
loo lin school of medicine, national
university of singapore, singapore
1

introduction

correspondence: de yun wang
department of otolaryngology, yong
loo lin school of medicine, national
university of singapore, 1e kent ridge
road, singapore 119228
tel +65 6772 5373
fax +65 6775 3820
email entwdy@nus.edu.sg

the frequency and impact of allergic diseases are often underestimated.1 a key
facilitator of the allergic response is immunoglobulin e (ige) that is present on the
surface of mast cells and basophils.2 interaction of the allergen with ige and its receptor complex leads to activation of these cells and release of the substances, including
histamine, that cause allergic symptoms.2
because of the central role of histamine in allergic responses, many allergic
conditions are treated with antihistamines, including allergic rhinitis and urticaria.3,4
antihistamines have been in clinical use for .70 years, and the pharmacological
characteristics of these agents have been evolving over that time.5
the objective of this article is to review the current burden of allergic rhinitis and
urticaria in asia pacific, to briefly describe the evolution of antihistamine pharmacology, and to systematically review the pharmacological characteristics and clinical
results of  xxxd338xxx , a new antihistamine that is highly selective for the h1 histamine
receptor.

585

submit your manuscript | www.dovepress.com

therapeutics and clinical risk management 2016:12 585‚Äì597

dovepress

¬© 2016 wang et al. this work is published and licensed by dove medical press limited. the full terms of this license are available at https://www.dovepress.com/terms.php
and incorporate the creative commons attribution ‚Äì non commercial (unported, v3.0) license (http://creativecommons.org/licenses/by-nc/3.0/). by accessing the work you
hereby accept the terms. non-commercial uses of the work are permitted without any further permission from dove medical press limited, provided the work is properly attributed. for permission
for commercial use of this work, please see paragraphs 4.2 and 5 of our terms (https://www.dovepress.com/terms.php).

http://dx.doi.org/10.2147/tcrm.s105189

powered by tcpdf (www.tcpdf.org)

abstract: allergic rhinitis and urticaria are common allergic diseases that may have a major
negative impact on patients‚Äô quality of life.  xxxd338xxx , a novel new-generation antihistamine
that is highly selective for the  xxxg1078xxx , has a rapid onset and prolonged duration
of action. this agent does not interact with the cytochrome p450 system and does not undergo
significant metabolism in humans, suggesting that it has very low potential for drug‚Äìdrug
interactions, and does not require dose adjustment in renal impairment. as  xxxd338xxx  is not
metabolized and is excreted largely unchanged, hepatic impairment is not expected to increase
systemic exposure above the drug‚Äôs safety margin.  xxxd338xxx  has demonstrated similar efficacy to
cetirizine and  xxxd1846xxx  in patients with seasonal allergic rhinitis and, in a vienna chamber
study, a potentially longer duration of action than fexofenadine in patients with asymptomatic
seasonal allergic rhinitis. it has also shown significant efficacy (similar to that of cetirizine) and
safety in the long-term treatment of perennial allergic rhinitis.  xxxd338xxx  showed similar efficacy
to levocetirizine in patients with chronic spontaneous urticaria and can be safely used at doses
of up to fourfold higher than standard dosage (80 mg once daily). the fourfold higher than
standard dose is specified as an acceptable second-line treatment option for urticaria in international guidelines.  xxxd338xxx  is generally well tolerated, both at standard and at supratherapeutic
doses, appears to have less sedative potential than other second-generation antihistamines, and
has no cardiotoxicity. based on its pharmacokinetic properties, efficacy, and tolerability profile,
 xxxd338xxx  will be valuable in the management of allergic rhinitis and urticaria.
keywords:  xxxd338xxx , second-generation antihistamines, allergic rhinitis, urticaria

dovepress

wang et al

therapeutics and clinical risk management downloaded from https://www.dovepress.com/ by 185.250.42.216 on 10-aug-2018
for personal use only.

research methodology
for the systematic review of  xxxd338xxx  data, a pubmed search
was undertaken of all publications including ‚Äú xxxd338xxx ‚Äù in
the title and/or abstract. no date limits were applied. all
preclinical and clinical trials were assessed for inclusion in
the review. attention was preferentially given to randomized
controlled trials, with appropriate controls for variation and
bias (eg, placebo group, blinding).

burden of allergic diseases in asia
pacific
allergic rhinitis
allergic rhinitis is a symptomatic condition of the nose
caused by allergen exposure and ige-mediated inflammation.6
allergic rhinitis is defined as intermittent or persistent,
and its severity is classed as mild or moderate-to-severe.6
historically, symptoms of the condition were categorized as
occupational, seasonal, or perennial, but this classification is
now unsatisfactory because these categories are not necessarily mutually exclusive.7 in 2001, the document ‚Äúallergic
rhinitis and its impact on asthma‚Äù (aria) recommended
replacing the terms ‚Äúseasonal‚Äù and ‚Äúperennial‚Äù rhinitis by
intermittent allergic rhinitis and persistent allergic rhinitis,
respectively.8 subsequently, ‚Äúintermittent‚Äù and ‚Äúpersistent‚Äù
are not precisely synonymous with seasonal and perennial
allergic rhinitis.
allergic rhinitis is frequently encountered in primary
care. patients report that allergic rhinitis has a marked
detrimental effect on their sleep, social life, quality of life,
and attendance and functioning at school and work.6,9‚Äì11
another issue is that allergic rhinitis commonly coexists
with other forms or allergic disease. considerable clinical
and epidemiological evidence also exists of an association
between asthma and allergic rhinitis.12 it has been estimated
that up to 75% of patients with asthma have rhinitis9,10 and
that approximately one-third of patients with allergic rhinitis
have asthma.10 comorbid links between allergic rhinitis and
sinusitis, conjunctivitis, otitis media, and nasal polyposis
have been documented, although the extent of such links
remains unclear.12 the economic burden of allergic rhinitis
is frequently underrated, and indirect costs of the disorder
are extensive.6,13
allergic rhinitis is a worldwide health problem, with
a prevalence estimated at between 10% and 30%, and it
is associated with considerable morbidity.11 the disorder
is estimated to affect the lives of .500 million people
worldwide.6 the burden is particularly high and increasing
in asia pacific, where many people now live in crowded

586

powered by tcpdf (www.tcpdf.org)

submit your manuscript | www.dovepress.com

dovepress

cities with high levels of environmental pollution.14 the
allergies in asia pacific survey reported an adult prevalence of 9% across the region, with 63% of patients having
seasonal or intermittent allergies.11 however, the prevalence
of allergic rhinitis subtypes does differ between countries
in asia pacific. in several southeast asian surveys, ~70%
of patients with allergic rhinitis had persistent disease
and ~30% had intermittent symptoms,15,16 whereas in the
people‚Äôs republic of china, ~25% of patients with allergic
rhinitis had the persistent form and 75% had intermittent
disease.17

urticaria
another common disease is urticaria. patients with urticaria
typically develop wheals (hives), angioedema, or both.4,18
usually, about half of all patients with urticaria have
associated angioedema.19 if the condition has a duration
of ,6 weeks, it is acute. if it persists for .6 weeks, or
recurs, it is chronic. symptoms of the disorder may endure
for several months or years.20 the most frequent causes
of acute urticaria, which may affect up to 15%‚Äì25% of
all individuals at some stage in their lives, are viral infections (especially affecting the upper respiratory tract), food
allergies, and drug adverse reactions.18 physical effects,
systemic disease, or long-term infection may also lead to
urticaria/angioedema.20,21 in patients with chronic urticaria,
the condition is often idiopathic (ie, has no discernible cause
in ~55%‚Äì80% of cases); this is known as chronic spontaneous urticaria.19,22 the counterpart is chronic inducible
urticaria, which is caused by physical stimuli such as cold,
heat, sun, or pressure.4
unfortunately, there are limited data on the burden of
urticaria in asia pacific. internationally, chronic spontaneous urticaria is estimated to have a point prevalence
of ~0.5%‚Äì1.0%.1,23,24 the peak age of occurrence is usually
between 20 years and 40 years, and typical disease duration
is 1‚Äì5 years, although this can be greater in many cases.
as with allergic rhinitis, chronic urticaria is a devastating
disorder that can have a major negative influence on a
patient‚Äôs quality of life, including vitality, sleep, mobility,
and social life.23,25‚Äì27 because of emotional distress, patients
with chronic spontaneous urticaria often have anxiety,
depression, and somatoform disorders.28 as a result, the
societal burden of the condition is great in terms of both
direct and indirect health care costs.23,26 the disorder is
often managed improperly, for example, with the repetitive use of oral corticosteroids that have significant safety
concerns.29

therapeutics and clinical risk management 2016:12

dovepress

 xxxd338xxx  in allergic rhinitis and urticaria

therapeutics and clinical risk management downloaded from https://www.dovepress.com/ by 185.250.42.216 on 10-aug-2018
for personal use only.

role of histamine and the h1
receptor subtype in ige-mediated
allergic diseases
histamine has a key role in the pathophysiology of allergic
inflammation.30 after exposure to an allergen, specific
antibodies of the ige type are produced in genetically predisposed individuals.30 these interact with receptors on the
surface of basophils and mast cells. the consequence is a
series of intracellular reactions culminating in exocytosis and
the release of histamine and other inflammatory mediators
such as  xxxd2973xxx  and cytokines.4,30 various
drugs (eg, morphine) can also cause direct displacement of
histamine from its storage granules.30
the consequences of histamine release include receptormediated smooth muscle cell contraction in the gastrointestinal
and respiratory tracts, sensory nerve stimulation, vasodilation,
plasma extravasation, and cellular recruitment, for example, to
urticarial lesions.4,30 these effects lead to, among other things,
erythema, flushing, nasal congestion, and pruritus.30
besides its mediatory activity in the early allergic response,
histamine contributes to the late allergic response by stimulating the production of cellular adhesion molecules, class ii
antigens, and cytokines.30

four principal histamine receptor subtypes exist: h1,
h2, h3, and h4. these are g-protein-coupled receptors that
transfer extracellular signals via g proteins, which act as
intermediaries between cell surface receptors and intracellular second messengers (figure 1).5,30 h1 and h2 receptors are
widely distributed throughout the body, but the h3 subtype is
mainly located in the central nervous system (cns) and the
h4 subtype in hematopoietic tissues.30 the allergic response
is primarily mediated by the  xxxg1078xxx  subtype.
h1 receptors are ubiquitous and are found in the adrenal medulla, cns, endothelial and epithelial cells, heart,
immune cells, sensory nerves, and smooth muscle.30 in the
cns, most of the postsynaptic actions of histamine are mediated by h1 receptors.30 this leads to activity on sleep‚Äìwake
cycles and probably explains the sedative effects noted with
first-generation antihistamines that cross the blood‚Äìbrain
barrier.21 via h1 receptors, histamine also causes smooth
muscle cell contraction in the gastrointestinal and respiratory tracts and stimulation of sensory nerves. outcomes
include pruritus, sneezing, increased vascular permeability,
and edema.30
antihistamines are not structurally related to histamine
and are not competitive antagonists of histamine binding

+lvwdplqh
+lvwdplqh

+lvwdplqh

+

++

+

3/&

*t

*v

$&

*lr
3,.

,3

f$03
'$*
0$3.

$nw

3.$
&d

3.&
&5(%

figure 1 intracellular signaling processes mediated by g-proteins after interaction of histamine with each receptor subtype.
abbreviations: ac, adenylate cyclase; akt, protein kinase b; camp,  xxxd1773xxx ; creb, camp response element-binding protein; dag, diacyl glycerol;
ip3, inositol triphosphate; mapk, mitogen-activated protein kinase; pi3k, phosphoinositide 3-kinase; pka,  xxxg1836xxx ; pkc, protein kinase c; plc, phospholipase c.

therapeutics and clinical risk management 2016:12

submit your manuscript | www.dovepress.com

dovepress

powered by tcpdf (www.tcpdf.org)

587

dovepress

therapeutics and clinical risk management downloaded from https://www.dovepress.com/ by 185.250.42.216 on 10-aug-2018
for personal use only.

wang et al

+lvwdplqh

+dqwlklvwdplqh

+uhfhswru

6hqvru\
qhxurq

6pdooeorrgyhvvhov

figure 2 direct downregulation of allergic inflammation by h1 antihistamines.

to h1 receptors; rather, antihistamines bind to different
sites from histamine on h1 receptors.5 therefore, these
antihistamines are inverse agonists rather than receptor
antagonists.5,31,32 they are referred to as ‚Äúh1 antihistamines‚Äù
rather than ‚Äúhistamine antagonists‚Äù.5
when h1 antihistamines are bound to h1 receptors, they
interfere with histamine action on sensory neurons and small
blood vessels, directly downregulating allergic inflammation
(figure 2). this downregulation also takes place indirectly
through transcription factor nuclear factor-kappab and through
calcium ion channels.33

history of antihistamines
histamine was discovered in 1907 by windaus and
vogt, after decarboxylation of the amino acid histidine.33‚Äì35
twenty years later, in 1927, emanuel identified histamine
as a constituent in normal tissues, notably the lungs,35 and in
1937, bovet and staub discovered antihistamines by demonstrating that synthesized agents could block the effects
of histamine.36 a few years later, in 1942, the first antihistamine, phenbenzamine (antergan), was introduced into
commercial use.5,33,34 this was closely followed by diphenhydramine,  xxxd375xxx , and chlorpheniramine in the
mid-1940s, promethazine later that decade, and hydroxyzine
in the 1950s.34,35
588

powered by tcpdf (www.tcpdf.org)

submit your manuscript | www.dovepress.com

dovepress

in 1957, daniel bovet received the nobel prize in physiology or medicine for his major therapeutic contribution.
more specifically, this was for his discoveries that synthesized
agents that inhibited the actions of various body substances,
particularly on the vascular and musculoskeletal systems.37
a key scientific discovery in the 1960s was that there
was more than one type of histamine receptor, and in 1966,
ash and schild suggested that the receptor blocked by antihistamines be called the  xxxg1078xxx , and agents blocking it
be called  xxxg1078xxx  antagonists.38
second-generation h1 antihistamines were introduced in
the 1980s. these agents represented a major enhancement
in antihistamine development because they had no or only
minimal sedative activity.5 furthermore, they were highly
selective for h1 receptors and were devoid of anticholinergic
activity.5 however, because of differences in drug specificity
for active transporter proteins (eg, p-glycoprotein [p-gp])
across the blood‚Äìbrain barrier, some second-generation
agents may enter the cns to a greater extent than others.5,39
cetirizine,  xxxd1846xxx , and loratadine, especially at high
dosages, are potentially more sedating than fexofenadine
and levocetirizine.5,40
another major drawback for some second-generation
agents was documentation in the late 1990s of significant cardiotoxicity. that is,  xxxd236xxx  and terfenadine were shown to
block the delayed rectifier k+ current (ikr), which is essential
for cardiac repolarization.5 this gave rise to the potential for
qt interval prolongation and life-threatening ventricular
arrhythmias such as torsade de pointes. such cardiotoxic
potential is now well established and has been extensively
reviewed.5 in most countries,  xxxd236xxx  and terfenadine have
now been withdrawn from the market.4,5,41,42
the evolution of second-generation antihistamines was
essentially based on experimentation with, and modification
of, forerunning first-generation compounds. further modifications then led to the introduction of other second-generation
agents: for example, stereoselective investigation led to
levocetirizine, and the knowledge of metabolism pathway of
loratadine led to the development of  xxxd1846xxx . a recent
development is the dual platelet activator factor and  xxxg1078xxx  antagonist rupatadine,43 which undergoes
extensive hepatic metabolism to produce active metabolites,
including  xxxd1846xxx .43,44
however,  xxxd338xxx  (figure 3) is a novel, benzimidazole‚Äìpiperidine derivative that is a highly selective h1
antihistamine.45,46 unlike certain other antihistamines, it is
a distinct chemical entity and not derived structurally from
other compounds in this class.32,47 it has been commercially
available internationally since march 2011.48
therapeutics and clinical risk management 2016:12

dovepress

 xxxd338xxx  in allergic rhinitis and urticaria

the highest number of desired features for a modern
antihistamine according to international aria guidelines
(table 2).

2

therapeutics and clinical risk management downloaded from https://www.dovepress.com/ by 185.250.42.216 on 10-aug-2018
for personal use only.

1
1

2

1
%hq]lplgd]roh¬±slshulglqh

2+

figure 3 chemical structure of  xxxd338xxx .

properties of the ‚Äúideal‚Äù
antihistamine
the aria guidelines stipulate that before a physician
prescribes pharmacotherapy, the following pertinent factors should be considered: the efficacy, safety and costeffectiveness of treatment, patient preference, the goals
of treatment, anticipated adherence to treatment, disease
severity, and control, as well as the presence of concurrent conditions.6 an extension of this is that the guidelines
also provide a detailed list of ‚Äúproperties that should be
met by oral h1-antihistamines‚Äù (table 1). fundamental
among these properties are potent and selective blocking
activity at h1 receptors, a rapid onset and long duration of
action, efficacy in allergic rhinoconjunctivitis, and against
all symptoms, including nasal obstruction, no interaction
with cytochrome p450 (cyp 450), no sedative activity or
cognitive or psychomotor impairment, no anticholinergic
activity, no cardiac safety concerns, and no potential for
tachyphylaxis.6
as outlined in the following sections,  xxxd338xxx  ‚Äì as
a modern, second-generation h 1 antihistamine ‚Äì has

 xxxd338xxx  pharmacology
preclinical trials
for any new chemical entity with potential for therapeutic
use, initial in vitro and in vivo preclinical studies are needed
to fully characterize the compound‚Äôs pharmacological profile. if efficacy is confirmed, and no major safety or toxicity
concerns are identified, progression can continue to phase i
clinical studies in healthy volunteers and then to phase ii‚Äìiii
clinical trials in the proposed indication.
with novel antihistamines (eg,  xxxd338xxx ), a specific goal
of in vitro studies is to confirm that the test agent has marked
selectivity ‚Äì high affinity for histamine h1 receptors, but
minimal effects at receptors for other mediators and amines.39
thus,  xxxd338xxx  (inhibition constant [ki] 44 nm) was shown to
dose-dependently inhibit 3h- xxxd3050xxx  binding to h1 receptors in the guinea pig cerebellum, with an affinity approximately threefold greater than that of cetirizine (ki 143 nm)
and fivefold greater than that of fexofenadine (ki 246 nm).49
similar findings were obtained in a human embryonic kidney
cell line (figure 4; ki 64 nm).49 additional in vitro trials
demonstrated that  xxxd338xxx  had no significant antagonist
activity at a diverse range of other receptors: h2, h3, and
h4, 5-ht2a, bradykinin b1, leukotriene d4, n-type voltagedependent calcium receptors, alpha1- and beta2-adrenoceptors, and
m1‚Äìm5 muscarinic receptors.39,49
in in vivo studies,  xxxd338xxx  showed antihistaminic activity
in various animal models and produced the following effects:
reduced histamine-induced capillary permeability in rats,

table 1 requirements of the ideal oral h1 antihistamine
pharmacological properties

efficacy

side effects

potent and selective activity at h1 receptors
other antiallergic activity
no clinically relevant pharmacokinetic interactions with
food, medication, or intestinal proteins
no interaction with cytochrome p450
no interaction with other diseases (thereby avoiding
toxic reactions)

effective in both intermittent
and persistent allergic rhinitis
effective against all nasal
symptoms, including obstruction
improves ocular symptoms
studies should be conducted
in young children and elderly
patients to assess efficacy

no sedation or cognitive or psychomotor
impairment
no anticholinergic activity
no weight gain
no cardiac safety concerns
potential use in pregnancy and breastfeeding
studies should be conducted in young children
and elderly patients to assess safety
prospective postmarketing safety analyses
should be performed

pharmacodynamics
rapid onset of action
long duration of action permitting once-daily dosing
no potential for tolerance development (tachyphylaxis)
note: reproduced from bousquet j, khaltaev n, cruz aa, et al; world health organization; ga(2)len; allergen. allergic rhinitis and its impact on asthma (aria)
2008 update (in collaboration with the world health organization, ga(2)len and allergen). allergy. 2008;63(suppl 86):8‚Äì160.6 with permission from john wiley
and sons. copyright ¬©2008.

therapeutics and clinical risk management 2016:12

submit your manuscript | www.dovepress.com

dovepress

powered by tcpdf (www.tcpdf.org)

589

powered by tcpdf (www.tcpdf.org)

590

submit your manuscript | www.dovepress.com

dovepress

ÔÉº

indicated for allergic
rhinoconjunctivitis?
indicated for allergic rhinitis?
indicated for urticaria?
pediatric indication?

10

6

severe renal impairment

6.5

none

caution

ÔÉª
ÔÉº (caution: drowsiness)

none

ÔÉª
ÔÉº (caution:
drowsiness)

ÔÉª

ÔÉª

ÔÉº (check drug response
when intending to drive)

ÔÉª
ÔÉª
ÔÉª

not mentioned

ÔÉª
caution

ÔÉº (in moderate to
severe)
ÔÉº (if concomitant renal
dysfunction)
ÔÉª (if renal function ok)

ÔÉº (give on empty stomach)
caution (very limited data)

ÔÉª

ÔÉª

ÔÉª

ÔÉº
ÔÉº
ÔÉº (children
$1 year)
caution (severe
impairment)
not mentioned

ÔÉª

27.0

++
¬±
+++
3.0

 xxxd1846xxx 

severe hepatic
impairment
6.5

ÔÉª
ÔÉº (caution:
somnolence)

ÔÉª
ÔÉª
caution

9.5

none

ÔÉº (impairment
unlikely)

not mentioned

ÔÉª
yes (antacids)

not mentioned

ÔÉª

ÔÉª

caution (in mild to
moderate)
ÔÉª

ÔÉº
ÔÉº
ÔÉº (children
$3 years)
ÔÉª

ÔÉª

11‚Äì15

+
¬±
¬±
1‚Äì3

fexofenadine

ÔÉº
ÔÉº
ÔÉº (children
$2 years)
caution

++
+
+++
2.6‚Äì4.0 (carebastine
metabolite)
15‚Äì19 (carebastine
metabolite)
ÔÉª

ebastine

ÔÉº (check drug
response when
intending to drive)
severe renal
impairment
6.5

ÔÉº
ÔÉº
ÔÉº (children
$2 years)
ÔÉº (in moderate-tosevere)
ÔÉº (if concomitant
renal dysfunction)
ÔÉº (for concomitant
moderate-to-severe
renal impairment)
ÔÉª
caution
unlikely (no
available data)
caution

ÔÉª

7.9

++
¬±
++
0.9

levocetirizine

6.5

none

ÔÉª
ÔÉª
potential (with inhibitors
of cyp3a4 and cyp2d6)
ÔÉª
ÔÉº (caution: drowsiness)

ÔÉª

ÔÉº (severe disease)

ÔÉª

ÔÉº
ÔÉº
ÔÉº (children $2 years)

ÔÉª

8.4

+
¬±
+++
1.0‚Äì1.5

loratadine

notes: adata obtained from summary of product characteristics for each individual compound (available from http://www.medicines.org.uk/emc/). bscore is derived from aria recommended antihistamine properties.6 (0.5 is given for
each characteristic where ‚Äúcaution‚Äù is recommended). ¬±, negligible; +, mild; ++, moderate; +++, marked.
abbreviations: tmax, time to peak plasma concentration; t1/2beta, elimination half-life; aria, allergic rhinitis and its impact on asthma; cyp, cytochrome p450.

number of aria recommended
antihistamine propertiesb

interaction with food?
use in pregnancy and lactation?
clinically relevant drug
interactions?
interaction with alcohol?
can patients drive and operate
machinery (ie, lack of sedative
potential)?
contraindications

dosage adjustment in renal
impairment?
dosage adjustment in hepatic
impairment?
dosage adjustment in elderly?

10.0

14.5

t1/2beta (hours)

ÔÉº
ÔÉº
ÔÉª (ongoing studies)

+
¬±
¬±
1.0

+++
¬±
not metabolized
1.3

 xxxg1078xxx  selectivity
affinity for h2/3 receptors
metabolism
tmax (hours)

ÔÉº/ÔÉª (some but not all
formulations)
ÔÉº
ÔÉº
ÔÉº (children 6‚Äì12 years)

cetirizine

 xxxd338xxx 

characteristic

table 2 clinical profile differences between various second-generation h1 antihistaminesa

therapeutics and clinical risk management downloaded from https://www.dovepress.com/ by 185.250.42.216 on 10-aug-2018
for personal use only.

wang et al
dovepress

therapeutics and clinical risk management 2016:12

%lodvwlqhsodvpd
frqfhqwudwlrq qjp/

 xxxd338xxx  in allergic rhinitis and urticaria

reduced microvascular leakage from guinea pig trachea and rat
dorsal skin, and reduced histamine-induced bronchospasm and
histamine- and compound 48/80-induced lethality in guinea
pigs.31,50 in these respects,  xxxd338xxx  had effects similar to those
of cetirizine but was more potent than fexofenadine.31,50
other antiallergic effects of  xxxd338xxx  were demonstrated
in various rodent models. specifically,  xxxd338xxx  reduced
vascular permeability mediated by passive cutaneous anaphylaxis in rats and reduced igg-dependent active cutaneous anaphylaxis. in mice,  xxxd338xxx  reduced ige-dependent
active cutaneous anaphylaxis and the passive arthus reaction
induced by ovine red blood cells.50 again, the magnitude of
these effects was similar to that produced by cetirizine and
superior to that produced by fexofenadine.50



%lodvwlqhfrqfhqwudwlrq
phgldqsuhglfwhglqwhutxduwloh
suhglfwhglqwhuydo
















       

7lph k

figure 5 predicted and observed plasma concentration‚Äìtime profile after oral
administration of a single 20 mg dose of  xxxd338xxx  to healthy volunteers.
note: reproduced from clin pharmacokinet, pharmacokinetic-pharmacodynamic
modelling of the antihistaminic (h1) effect of  xxxd338xxx , 2009;48:543‚Äì554, jauregizar
n, de la fuente l, lucero ml, sologuren a, leal n, rodr√≠guez m,51 copyright ¬©2009,
with permission of springer.
abbreviation: h, hours.

pharmacokinetic profile
 xxxd338xxx  is rapidly absorbed after oral administration.51 in
rats, its onset of antihistaminic action is ~30 minutes postdose, the maximum clinical effect persists from 30 minutes
to 8 hours postdose, and the drug has a prolonged duration
of action ($16 hours; figure 5).51
in healthy volunteers given a single oral dose of  xxxd338xxx  20 mg, the mean peak plasma concentration (cmax)
was 220 mug/l, attained at 1.3 hours postdose (tmax).51 the
apparent volume of distribution (vd) was 1.29 l/kg, terminal
elimination half-life (t1/2beta) was 14.5 hours, and total plasma
clearance was 18.1 l/h;  xxxd338xxx  was 84%‚Äì90% bound to
plasma proteins.51
the oral bioavailability of  xxxd338xxx  is ~60%.52 however,
in healthy volunteers given a single 20 mg dose, concurrent food intake reduced bioavailability by 30% (high-fat
meal) or 25% (low-fat meal) relative to fasting conditions.48
concomitant ingestion of grapefruit juice also reduced
6shflilfelqglqj 

therapeutics and clinical risk management downloaded from https://www.dovepress.com/ by 185.250.42.216 on 10-aug-2018
for personal use only.

dovepress




,& q0



. q0





¬±

¬±

¬±

¬±

%lodvwlqh pro/

¬±

¬±

figure 4 affinity of  xxxd338xxx  to human h1 receptors expressed in hek-293 cell.
note: reproduced from drugs r d, a preclini¬≠cal pharmacology of  xxxd338xxx , a
new selective  xxxg1078xxx  antagonist: receptor selectivity and in vitro
antihistaminic activity, 2005;6:371‚Äì384, corcostegui r, labeaga l, innerarity a,
berisa a, orjales a,49 copyright ¬©2005, with permission of springer.

therapeutics and clinical risk management 2016:12

 xxxd338xxx  bioavailability by 30%.48 therefore, it is recommended that  xxxd338xxx  be taken in the fasting state.48
as previously outlined, and as listed in aria guidelines,6
one of the key qualities of an ideal oral h1 antihistamine is
to have no interaction with cyp 450. however, some oral
h1 antihistamines (eg, loratadine, rupatadine) are extensively
transformed to active metabolites by the cyp system in
the liver. this creates significant potential for drug‚Äìdrug
interactions.7 importantly,  xxxd338xxx  does not interact significantly, either as an inhibitor or as a inducer, with the cyp
enzyme system in vitro,53 and it does not undergo significant
metabolism in humans.48 approximately 95% of an oral
 xxxd338xxx  dose is excreted unchanged in the urine (28%) and
feces (67%).48 this elimination profile markedly reduces the
potential for metabolic drug‚Äìdrug interactions.
oral  xxxd338xxx  can be administered to patients independently of glomerular filtration rate.54 no dosage adjustments
are needed in patients with mild, moderate, or severe renal
impairment.54 however, in patients with moderate‚Äìsevere
renal insufficiency who are being treated with p-gp inhibitors,
such as cyclosporine, diltiazem, erythromycin, ketoconazole,
or ritonavir,  xxxd338xxx  should not be administered; these
inhibitors may increase plasma  xxxd338xxx  levels and lead to
increased potential for adverse events.48
as this agent is not metabolized and is excreted largely
unchanged, hepatic impairment is not expected to increase
systemic exposure above the safety margin of the drug.55
therefore, no dosage adjustment is needed in patients with
hepatic impairment.48
 xxxd338xxx  is a substrate for several transporter proteins
in the p-gp and organic anion-transporter protein class.
these transporters have a significant influence on the

submit your manuscript | www.dovepress.com

dovepress

powered by tcpdf (www.tcpdf.org)

591

dovepress

 xxxd338xxx  efficacy
the  xxxd338xxx  clinical trial program was designed before
the publication of the 2001 aria guidelines, so the patient
inclusion criteria were based on the former classification of
seasonal and perennial allergic rhinitis.

seasonal allergic rhinitis
in two multicenter, randomized, double-blind, placebocontrolled trials in a total of 1,402 patients with seasonal
allergic rhinitis, the efficacy of  xxxd338xxx  was compared with
that of cetirizine57 and  xxxd1846xxx .58
in one trial,57 over a 2-week treatment period,  xxxd338xxx 
and cetirizine displayed similar efficacy: both compounds
significantly reduced total symptom score (tss = nasal
symptom score [nss] + nonnasal symptom score [nnss]),
relative to placebo.57 the percentage decrease from baseline
in nss (for nasal obstruction, rhinorrhea, sneezing, and
itching) was significantly greater (p,0.001) with  xxxd338xxx 
(-42.4%) and cetirizine (-48.2%) than placebo (-26.9%).
the same was true for nnss (for ocular tearing, redness, and
itching): corresponding percentage changes from baseline
were -49.8%, -51.0%, and -27.6% (figure 6).57
in the other trial,58 similar results to the first study were
obtained for  xxxd338xxx  and  xxxd1846xxx  versus placebo over
a 2-week treatment period. regarding the primary study end
point ‚Äì area under the curve of tss (auctss) ‚Äì the mean
value was significantly lower (p,0.001) for  xxxd338xxx  (98.4)
and  xxxd1846xxx  (100.5) than for placebo (118.4).58
in a vienna challenge chamber study performed outside the pollen season in 75 individuals with asymptomatic
seasonal allergic rhinitis, an antihistamine or placebo was
administered immediately before allergen challenge. 56
the three antihistamines tested,  xxxd338xxx , cetirizine, and

592

powered by tcpdf (www.tcpdf.org)

submit your manuscript | www.dovepress.com

dovepress

3odfher q 
&hwlul]lqhpj q 
%lodvwlqhpj q 
1166

166


3hufhqwdjhriuhgxfwlrq
iurpedvholqh

pharmacokinetic profile of various drugs since p-gp can
be considered as an efflux pump, whereas organic aniontransporter proteins can facilitate drug uptake.55  xxxd338xxx  has
shown a high affinity for the p-gp efflux pump;55 this effect
restricts transit across the blood‚Äìbrain barrier and limits the
potential for sedation.30,32
differences between the transporter protein-binding
profiles of second-generation antihistamines may explain
some of the substantial differences in clinical activity and
tolerability that exist between agents in this class (table 2).
further research in this area is clearly warranted. indeed,
transporter protein interactions might ultimately explain
important clinical differences, such as the potentially longer
duration of action for  xxxd338xxx  over fexofenadine.56

¬±
¬±
¬±

¬±

¬±

¬±
¬±
¬±

¬±

¬±

¬±

¬±
figure 6 percentage decrease from baseline in nss and nnss in a randomized,
double-blind, placebo-controlled study of  xxxd338xxx  versus cetirizine in patients with
seasonal allergic rhinitis.
note: *p,0.001 versus placebo. data from kuna et al.57
abbreviations: nss, nasal symptom score; nnss, nonnasal symptom score.

fexofenadine, were all significantly effective (p,0.001)
regarding percentage mean decrease in total nss versus
placebo at all time points, including early (1‚Äì4 hours) and late
(22‚Äì26 hours) after dosing.56 however, at the latter time point,
 xxxd338xxx  (p=0.0012) and cetirizine (p,0.001) were both
significantly more effective than fexofenadine (figure 7).57
as already mentioned, this suggests that  xxxd338xxx  and cetirizine have a longer duration of action than fexofenadine.56
 xxxd338xxx  is indicated for allergic rhinoconjunctivitis,
whereas not all antihistamines have this specific indication
(table 2). an analysis of  xxxd338xxx  clinical trials showed
that this agent was significantly more effective than placebo
at relieving ocular symptoms (p,0.001), including both
krxuvdiwhu
guxjdgplqlvwudwlrq

3hufhqwdjhriphdq7166
uhgxfwlrqiurpsodfher

therapeutics and clinical risk management downloaded from https://www.dovepress.com/ by 185.250.42.216 on 10-aug-2018
for personal use only.

wang et al

¬±krxuvdiwhu
guxjdgplqlvwudwlrq


¬±
¬±
¬±
¬±
¬±
¬±

¬±
¬±

¬±
¬±

)h[rihqdglqhpj
&hwlul]lqhpj

¬±
¬±





%lodvwlqhpj
figure 7 effects of three antihistamines on tnss in a vienna challenge chamber
study performed in 75 individuals with asymptomatic seasonal allergic rhinitis.
notes: *p,0.001 versus placebo, #p=0.0012 for  xxxd338xxx  versus fexofenadine,
&
p,0.001 for cetirizine versus fexofenadine. data from horak et al.56
abbreviation: tnss, total nasal symptom score.

therapeutics and clinical risk management 2016:12

dovepress

 xxxd338xxx  in allergic rhinitis and urticaria

a randomized, double-blind, placebo-controlled trial, conducted in europe, argentina, and south africa, compared
the efficacy of  xxxd338xxx  with that of cetirizine and placebo
over 4 weeks in 651 patients with perennial allergic rhinitis;
in an open-label, extension phase, 513 patients were treated
with  xxxd338xxx  20 mg once daily for 12 months,60 the longest
analysis to date with any antihistamine. there was no statistically significant difference between groups in auctss from
baseline to day 28.60 however, there was a region-specific
effect: primary efficacy was significantly better in the antihistamine versus placebo groups in europe and argentina
(p=0.039). conversely, no significant difference was evident
in south africa, where patients reported a relatively high
placebo response rate.60 during the open-label extension
phase,  xxxd338xxx  significantly reduced tss, nss, nss without
blocked symptoms, nnss, and constituent symptoms after
both the patients‚Äô and investigators‚Äô assessments.60 the longterm extension phase of this study also demonstrated that
 xxxd338xxx  was safe and well tolerated during extended use.60
the proven efficacy of  xxxd338xxx  in perennial allergic
rhinitis is important for physicians in the southeast asian
region, given the high proportion of patients who have persistent allergic rhinitis in this part of the world.15,16

urticaria
a 4-week, multicenter, randomized, double-blind, placebocontrolled study compared the efficacy of  xxxd338xxx  with that
of levocetirizine in a total of 525 patients with chronic idiopathic urticaria.61  xxxd338xxx  and levocetirizine were similarly
effective and both significantly more effective than placebo
(p,0.001), in reducing mean tss (for pruritus severity,
number of wheals, and maximum size of wheals) over 2 weeks
and 4 weeks (figure 8).61 significantly greater improvements
than placebo were noted regarding reduction in dermatology
life quality index score:  xxxd338xxx  -9.45 (p,0.001), levocetirizine -8.94 (p,0.001), and placebo -5.93.61
 xxxd338xxx  is more effective than cetirizine at limiting the
early allergic response, according to the results of a study in
volunteers.62 volunteers received a single oral dose of  xxxd338xxx  20 mg, cetirizine 10 mg, or placebo, before provocation
of a cutaneous wheal and flare response. at 1.5 hours after
the provocation, there was significantly greater inhibition of the
wheal and flare response among those who received  xxxd338xxx 
than in those who received cetirizine or placebo (p,0.02).62

therapeutics and clinical risk management 2016:12



0hdqfkdqjhvlq766
iurpedvholqh

therapeutics and clinical risk management downloaded from https://www.dovepress.com/ by 185.250.42.216 on 10-aug-2018
for personal use only.

perennial allergic rhinitis

'd\

'd\

reflexive and instantaneous symptoms (itching, tearing, and
conjunctival redness).59

¬±
¬±
¬±

¬±

¬±

¬±
¬±
¬±
¬±
¬±

¬±

¬±
¬±

¬±

3odfher q 
/hyrfhwlul]lqhpj q 
%lodvwlqhpj q 

figure 8 mean decreases in tss during 4 weeks‚Äô administration of  xxxd338xxx  or
levocetirizine to patients with chronic spontaneous urticaria.
notes: *p,0.001 versus placebo. reproduced from zuberbier t, oanta a,
bogacka e, et al;  xxxd338xxx  international work¬≠ing group. comparison of the efficacy
and safety of  xxxd338xxx  20 mg vs levocetirizine 5 mg for the treatment of chronic
idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled
study. allergy. 2010;65:516‚Äì528.61 with permission from john wiley and sons.
copyright ¬©2009.
abbreviation: tss, total symptom score.

while spontaneous urticaria is the most common
form,23,63 ~25% of patients with urticaria have an inducible
form.  xxxd338xxx  has been evaluated at a range of doses, from
the recommended dose of 20 mg to four times this dosage (ie,
80 mg once daily) in a randomized, double-blind, placebocontrolled, 7-day study in patients with acquired cold urticaria. a response rate (percentage of patients symptom free)
of 60% was obtained.64 the incidence of adverse events at
all  xxxd338xxx  doses (20 mg, 40 mg, and 80 mg) was similar to
placebo,64 demonstrating that  xxxd338xxx  is well tolerated even
at doses two or four times higher than the recommended daily
dose. further research is needed to demonstrate its efficacy
in other inducible forms of urticaria, which may include
urticaria induced by pressure, heat, sun exposure, exercise,
or contact with specific allergens.
the use of supratherapeutic doses of  xxxd338xxx  in the
study of patients with cold urticaria is consistent with international guideline recommendations. joint guidelines from
the european academy of allergy and clinical immunology
(eaaci), the global allergy and asthma european network
(ga2len), the european dermatology forum (edf), and
the world allergy organization (wao) now clearly stipulate
that ‚Äúmodern second generation h1-antihistamines are to be
used as first line treatment of urticaria.‚Äù4 in addition, these
guidelines recommend ‚Äúa trial of up to fourfold dose of modern second generation h1-antihistamines as second-line in the
algorithm of treatment.‚Äù4 the aim of this recommendation
is to attain complete control of symptoms4 since more than
one-third of patients with chronic urticaria are refractory to
standard-dosage antihistamine therapy.11

submit your manuscript | www.dovepress.com

dovepress

powered by tcpdf (www.tcpdf.org)

593

dovepress

a comparison of clinical trial data for second-generation
antihistamines in chronic urticaria suggests that this  xxxd338xxx  dosage (80 mg/d) is significantly more effective than
supratherapeutic dosages of  xxxd1846xxx  and levocetirizine
(figure 9).22 however, use of these compounds at four times
higher than standard doses is certain to raise safety concerns
among some physicians. for instance, the sedative potential
of cetirizine,  xxxd1846xxx , and loratadine will likely be
markedly greater than that of  xxxd338xxx , fexofenadine, and
levocetirizine.5,40 concerns at high dosage may also manifest
about the potential for qtc prolongation, particularly given
the unfavorable history of  xxxd236xxx  and terfenadine.31
however,  xxxd338xxx  at therapeutic and supratherapeutic doses
in healthy volunteers had no significant influence on ventricular repolarization.  xxxd338xxx  doses of 20 mg and 100 mg
had no clinically significant effect on qtc interval.  xxxd338xxx 
20 mg was also administered with ketoconazole and had no
effect on qtc interval when used in combination.42

 xxxd338xxx  safety
the safety database for  xxxd338xxx  comprises .5,000 individuals involved in well-designed clinical trials. a total
of .3,000 patients were treated with  xxxd338xxx , generally at a
dosage of 20 mg once daily for 2‚Äì4 weeks.39 the incidence of
treatment-related adverse events was not markedly different
between  xxxd338xxx  (12.7%), placebo (12.8%), and other antihistamines: cetirizine (14.3%),  xxxd1846xxx  (11.6%), and
levocetirizine (15.8%).39
in the pooled analysis of adverse events, the incidence of
treatment-related cns events was similar between  xxxd338xxx 
and placebo. headache and dizziness showed a similar
incidence between all active treatment and placebo groups.
5hvsrqvhudwh
sdwlhqwvv\pswrpiuhh

therapeutics and clinical risk management downloaded from https://www.dovepress.com/ by 185.250.42.216 on 10-aug-2018
for personal use only.

wang et al








'hvorudwdglqhpj q 
/hyrfhwlul]lqhpj q 
%lodvwlqhpj q 












%lodvwlqhpj /hyrfhwlul]lqh
rqfhgdlo\
pjrqfh
gdlo\

'hvorudwdglqh
pjrqfh
gdlo\

figure 9 efficacy of increased dosages of second-generation antihistamines in
chronic urticaria.
note: adapted from sanchez-borges m, ansotegui i, jimenez jm, rojo mi, serrano
c, ya√±ez a. comparative efficacy of non-sedating antihistamine updosing in patients
with chronic urticaria. world allergy organ j. 2014;7:33.22

594

powered by tcpdf (www.tcpdf.org)

submit your manuscript | www.dovepress.com

dovepress

somnolence occurred with a similar frequency in  xxxd338xxx 
(3.5%) and placebo recipients (2.9%). however, cetirizine was
associated with a significantly greater incidence of somnolence
(7.6%, p,0.001) than  xxxd338xxx  and levocetirizine with a significantly greater incidence (6.1%, p,0.05) than placebo.39
in a large-scale, randomized, double-blind study in a total
of 683 patients with seasonal allergic rhinitis,  xxxd338xxx  versus
cetirizine was linked with a significantly smaller incidence
of all drug-related events (14.5% vs 24.6%, p#0.01), fatigue
(0.4% vs 4.8%, p#0.01), and somnolence (1.8% vs 7.5%).57
the clear implication from these data is that, in everyday
clinical practice,  xxxd338xxx  has a better safety profile and
therapeutic index than cetirizine.
high-dosage  xxxd338xxx  (40 mg or 80 mg once daily),
in line with eaaci/ga2len/edf/wao guidelines,4 has
demonstrated efficacy in the treatment of urticaria.64 in a
study in patients with acquired cold urticaria,  xxxd338xxx  was
well tolerated without evidence of an increased incidence of
sedation at doses up to 80 mg/day.64
the cns effects of  xxxd338xxx  80 mg were also evaluated
in healthy volunteers.65 although objective test results (d2
cancellation test, simple reaction time) revealed minor ‚Äì yet
significant ‚Äì impairment, high-dosage  xxxd338xxx  did not significantly alter subjective test results (visual analog scale score,
profile of mood states questionnaire score).65 the effects of
 xxxd338xxx  80 mg were equivalent to those of standard-dose
hydroxyzine.65

lack of sedation
in several studies utilizing an active control ‚Äúarm‚Äù comprising the first-generation agent hydroxyzine, standard-dosage
 xxxd338xxx  (20 mg once daily) and higher-dosage  xxxd338xxx 
(40 mg once daily in one study66 and a single 80 mg dose in
another65) had no significant effects on various objective
measures of psychomotor and driving performance.65,66
moreover, when  xxxd338xxx  was administered concurrently
with lorazepam, the extent of psychomotor impairment
was similar to that when lorazepam was administered
alone.39 also, no interaction has been identified between
alcohol and standard-dosage  xxxd338xxx . objective testing
in a placebo-controlled trial revealed an extent of psychomotor impairment with  xxxd338xxx  20 mg + alcohol similar
to that noted after ingestion of alcohol alone, whereas
standard doses of either hydroxyzine or cetirizine exacerbated the impairing effects of alcohol on psychomotor
performance.65
a positron emission tomography study of brain  xxxg1078xxx  occupancy in 12 healthy volunteers revealed that this

therapeutics and clinical risk management 2016:12

therapeutics and clinical risk management downloaded from https://www.dovepress.com/ by 185.250.42.216 on 10-aug-2018
for personal use only.

dovepress

 xxxd338xxx  in allergic rhinitis and urticaria

parameter was close to zero for  xxxd338xxx  (-3.92%), and therefore similar to placebo. conversely, the first-generation agent
hydroxyzine had significantly greater occupancy (+54%).67,68
this confirms that  xxxd338xxx  has relatively limited potential to
cross the blood‚Äìbrain barrier and interact with cns h1 receptors. based on published data for other agents, it appears that
 xxxd338xxx  has the lowest rate of brain  xxxg1078xxx  occupancy
of all the available antihistamines (table 3).67,69‚Äì73 therefore,
it has minimal capacity to cause cns adverse effects.

no qtc prolongation
the cardiac safety profile of  xxxd338xxx  was confirmed in various studies that included concurrent administration of the
cyp450/p-gp inhibitors ketoconazole, erythromycin, and
diltiazem and in detailed qt studies40,74 conducted in accordance with international conference on harmonization (ich)
guidelines. to date,  xxxd338xxx  is the only commercially available antihistamine that has been tested using the stringent ich
e/14 criteria for effects on qt interval. this study showed
no significant effect on qtc interval using these stringent
criteria.42,69 these studies confirmed that standard-dosage
 xxxd338xxx  has a good cardiac safety profile and that uptitration
of the  xxxd338xxx  dose to 220 mg, or administration of the drug
with cyp450 or p-gp inhibitors, does not alter this safety
profile.42,69 in clinical trials,  xxxd338xxx  was not associated with
any clinically relevant qtc interval prolongation.39

 xxxd338xxx  administration in children
the efficacy and safety of  xxxd338xxx  in children aged 12 years
or less, who frequently have allergic disorders, have not yet
been established. for registration of the adult formulation
of  xxxd338xxx , the clinical plan was developed to comply with
the european medicines agency guidelines and therefore
the cut off age is 12 years. however,  xxxd338xxx  has been
table 3 percentage of brain  xxxg1078xxx  occupancy (mean) after
oral administration of antihistamines using pet67,69‚Äì73

bilastine67
fexofenadine73
ebastine72
terfenadine69,70
azelastine70
cetirizine73
d-chlorpheniramine71
hydroxyzine67
d-chlorpheniramine69‚Äì71
d-chlorpheniramine71

dose (mg)

mean  xxxg1078xxx 
occupancy on pet (%)

20
120
10
60
1
20
1
25
2
5

-3.92
-0.1
9.9‚Äì14.4
12.1‚Äì17.2
20.3
26.0
40.4
53.95
60.4‚Äì76.8
85.5

abbreviation: pet, positron emission tomography.

therapeutics and clinical risk management 2016:12

investigated according to a paediatric investigation plan that
was designed according to the requirements of the european
medicines agency paediatric committee. publication of
data from the paediatric investigation plan is awaited with
interest.

conclusion
currently, there are a number of unmet needs in the management of allergic conditions in asia pacific,14,75 with many
patients still experiencing sedation from the use of older
antihistamines.68 when second-generation h1 antihistamines were introduced in the 1980s, they revolutionized the
treatment of allergic disorders because of a lack of, or only
minimal, sedative potential.39
the proven efficacy and safety profile of  xxxd338xxx , its
low potential for cns impairment when coadministered
with alcohol or for metabolic drug‚Äìdrug interactions, and no
need for dose adjustments confirm that this compound has
a forerunning place in therapy among second-generation h1
antihistamines in the management of urticaria and allergic
rhinitis, including allergic rhinoconjunctivitis (intermittent
and persistent).

acknowledgments
the authors would like to acknowledge menarini asiapacific holdings pte ltd for providing logistic support and
funding for the consensus meeting and for commissioning
mims pte ltd to provide writing assistance and editorial
support. the views expressed in this manuscript are solely
those of the authors.

disclosure
the authors report no conflicts of interest in this work.

references

1. pawankar r, canonica gw, holgate st, lockey rf, blaiss ms. wao
white book on allergy: update 2013. milwaukee, wi: world allergy
organization; 2013.
2. kumar y, bhatia a. immunopathogenesis of allergic disorders: current
concepts. expert rev clin immunol. 2013;9:211‚Äì226.
3. brozek jl, bousquet j, baena-cagnani ce, et al; global allergy and
asthma european network; grading of recommendations assessment,
development and evaluation working group. allergic rhinitis and its
impact on asthma (aria) guidelines: 2010 revision. j allergy clin
immunol. 2010;126:466‚Äì476.
4. zuberbier t, aberer w, asero r, et al; european academy of allergy
and clinical immunology; global allergy and asthma european
network; european dermatology forum; world allergy organization.
the eaaci/ga(2) len/edf/wao guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and
update. allergy. 2014;69:868‚Äì887.
5. church ds, church mk. pharmacology of antihistamines. world allergy
organ j. 2011;4(3 suppl):s22‚Äìs27.

submit your manuscript | www.dovepress.com

dovepress

powered by tcpdf (www.tcpdf.org)

595

dovepress

therapeutics and clinical risk management downloaded from https://www.dovepress.com/ by 185.250.42.216 on 10-aug-2018
for personal use only.

wang et al
6. bousquet j, khaltaev n, cruz aa, et al; world health organization;
ga(2)len; allergen. allergic rhinitis and its impact on asthma (aria)
2008 update (in collaboration with the world health organization,
ga(2)len and allergen). allergy. 2008;63(suppl 86):8‚Äì160.
7. bousquet j, schunemann hj, samolinski b, et al; world health organization collaborating center for asthma and rhinitis. allergic rhinitis
and its impact on asthma (aria): achievements in 10 years and future
needs. j allergy clin immunol. 2012;130:1049‚Äì1062.
8. bousquet j, van cauwenberge p, khaltaev n; aria workshop group;
world health organization. allergic rhinitis and its impact on asthma.
j allergy clin immunol. 2001;108(5 suppl):s147‚Äìs334.
9. angier e, willington j, scadding g, et al; british society for allergy &
clinical immunology (bsaci) standards of care committee. management of allergic and non-allergic rhinitis: a primary care summary of
the bsaci guideline. prim care respir j. 2010;19:217‚Äì222.
10. canonica gw, bousquet j, mullol j, scadding gk, virchow jc. a survey
of the burden of allergic rhinitis in europe. allergy. 2007;62(suppl 85):
17‚Äì25.
11. meltzer eo, blaiss ms, naclerio rm, et al. burden of allergic rhinitis:
allergies in america, latin america, and asia-pacific adult surveys.
allergy asthma proc. 2012;33(suppl 1):s113‚Äìs141.
12. annesi-maesano i, beyer a, marmouz f, mathelier-fusade p,
vervloet d, bauchau v. concurrent allergic diseases: a cross-sectional
study in a french population. allergy. 2006;61:390‚Äì391.
13. blaiss ms. allergic rhinitis: direct and indirect costs. allergy asthma
proc. 2010;31:375‚Äì380.
14. prepageran n. managing allergic rhinitis and chronic rhinosinusitis in developing countries ‚Äì focus on asia pacific. in: akdis ca,
hellings pw, agache i, editors. global atlas of allergic rhinitis and
chronic sinusitis. zurich: european academy of allergy and clinical
immunology; 2015:400‚Äì403.
15. asha‚Äôari za, yusof s, ismail r, che hussin cm. clinical features of
allergic rhinitis and skin prick test analysis based on the aria classification: a preliminary study in malaysia. ann acad med singapore.
2010;39:619‚Äì624.
16. bunnag c, jareoncharsri p, tantilipikorn p, vichyanond p, pawankar r.
epidemiology and current status of allergic rhinitis and asthma in
thailand ‚Äì aria asia-pacific workshop report. asian pac j allergy
immunol. 2009;27:79‚Äì86.
17. zhang l, han d, huang d, et al. prevalence of self-reported allergic
rhinitis in eleven major cities in china. int arch allergy immunol. 2009;
149:47‚Äì57.
18. zuberbier t. urticaria. allergy. 2003;58:1224‚Äì1234.
19. ferrer m, sastre j, jauregui i, et al. effect of antihistamine up-dosing in
chronic urticaria. j investig allergol clin immunol. 2011;21(suppl 3):
34‚Äì39.
20. muller ba. urticaria and angioedema: a practical approach. am fam
physician. 2004;69:1123‚Äì1128.
21. carstens e, akiyama t. itch: mechanisms and treatment. boca raton,
fl: frontiers in neuroscience; 2014.
22. sanchez-borges m, ansotegui i, jimenez jm, rojo mi, serrano
c, ya√±ez a. comparative efficacy of non-sedating antihistamine
updosing in patients with chronic urticaria. world allergy organ j.
2014;7:33.
23. maurer m, weller k, bindslev-jensen c, et al. unmet clinical needs in
chronic spontaneous urticaria. a ga(2)len task force report. allergy.
2011;66:317‚Äì330.
24. zuberbier t, balke m, worm m, edenharter g, maurer m. epidemiology of urticaria: a representative cross-sectional population survey. clin
exp dermatol. 2010;35:869‚Äì873.
25. staevska m, gugutkova m, lazarova c, et al. night-time sedating
h1-antihistamine increases daytime somnolence but not treatment
efficacy in chronic spontaneous urticaria: a randomized controlled trial.
br j dermatol. 2014;171:148‚Äì154.
26. pawankar r, holgate st, canonica gw, lockey rf, blaiss ms,
editors. wao white book on allergy: update 2013, executive summary.
milwaukee, wi: world allergy organization; 2013.

596

powered by tcpdf (www.tcpdf.org)

submit your manuscript | www.dovepress.com

dovepress

27. baiardini i, giardini a, pasquali m, et al. quality of life and patients‚Äô
satisfaction in chronic urticaria and respiratory allergy. allergy. 2003;
58:621‚Äì623.
28. staubach p, dechene m, metz m, et al. high prevalence of mental
disorders and emotional distress in patients with chronic spontaneous
urticaria. acta derm venereol. 2011;91:557‚Äì561.
29. zazzali jl, broder ms, chang e, chiu mw, hogan dj. cost, utilization, and patterns of medication use associated with chronic idiopathic
urticaria. ann allergy asthma immunol. 2012;108:98‚Äì102.
30. mahdy am, webster nr. histamine and antihistamines. anaesth
intensive care med. 2014;15:5.
31. bousquet j, ansotegui i, canonica gw, et al. establishing the place
in therapy of  xxxd338xxx  in the treatment of allergic rhinitis according to
aria: evidence review. curr med res opin. 2012;28:131‚Äì139.
32. ridolo e, montagni m, bonzano l, incorvaia c, canonica gw.  xxxd338xxx :
new insight into antihistamine treatment. clin mol allergy. 2015;13:1.
33. simons fe, simons kj. histamine and h1-antihistamines: celebrating
a century of progress. j allergy clin immunol. 2011;128:1139‚Äì1150.
34. figueroa k, shankley n. one hundred years of histamine research. adv
exp med biol. 2010;709:1‚Äì9.
35. emanuel mb. histamine and the antiallergic antihistamines: a history
of their discoveries. clin exp allergy. 1999;29(suppl 3):1‚Äì11.
[discussion 12].
36. bovet d, staub a. action protectrice des ethers phenologiques au
cours de l‚Äôintoxication histaminique. acrs soc biol. (paris). 1937;
124:527‚Äì549. french.
37. janssens mm. introduction. second-generation antihistamines. clin
rev allergy. 1993;11:1‚Äì3.
38. ash as, schild ho. receptors mediating some of the actions of histamine. br j pharmacol. 1966;27:427‚Äì429.
39. church mk. safety and efficacy of  xxxd338xxx : a new h(1)-antihistamine
for the treatment of allergic rhinoconjunctivitis and urticaria. expert
opin drug saf. 2011;10:779‚Äì793.
40. wallace dv, dykewicz ms, bernstein di, et al; joint task force on
practice; american academy of allergy; asthma & immunology;
american college of allergy; asthma and immunology; joint council
of allergy, asthma and immunology. the diagnosis and management of
rhinitis: an updated practice parameter. j allergy clin immunol. 2008;
122(2 suppl):s1‚Äìs84.
41. estelle f, simons r. h1-receptor antagonists: safety issues. ann allergy
asthma immunol. 1999;83:481‚Äì488.
42. tyl b, kabbaj m, azzam s, et al. lack of significant effect of  xxxd338xxx  administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: results of
a thorough qt study (tqts) with qt-concentration analysis. j clin
pharmacol. 2012;52:893‚Äì903.
43. picado c. rupatadine: pharmacological profile and its use in the
treatment of allergic disorders. expert opin pharmacother. 2006;7:
1989‚Äì2001.
44. sun c, li q, pan l, et al. development of a highly sensitive lc-ms/ms
method for simultaneous determination of rupatadine and its two active
metabolites in human plasma: application to a clinical pharmacokinetic
study. j pharmaceut biomed anal. 2015;111:163‚Äì168.
45. kowal k, dubuske l.  xxxd338xxx  as a potential treatment in allergic
rhinitis. am j rhinol allergy. 2014;28:312‚Äì316.
46. davila i, sastre j, mullol j, et al. effect of  xxxd338xxx  upon nasal obstruction. j investig allergol clin immunol. 2011;21(suppl 3):2‚Äì8.
47. wolthers od.  xxxd338xxx : a new nonsedating oral h1 antihistamine for
treatment of allergic rhinoconjunctivitis and urticaria. biomed res int.
2013;2013:626837.
48. menarini farmaceutica internazionale srl.  xxxd338xxx  20 mg tablets:
summary of product characteristics. buckinghamshire: menarini
farmaceutica internazionale srl; 2012.
49. corcostegui r, labeaga l, innerarity a, berisa a, orjales a. preclinical pharmacology of  xxxd338xxx , a new selective  xxxg1078xxx 
antagonist: receptor selectivity and in vitro antihistaminic activity.
drugs r d. 2005;6:371‚Äì384.

therapeutics and clinical risk management 2016:12

therapeutics and clinical risk management downloaded from https://www.dovepress.com/ by 185.250.42.216 on 10-aug-2018
for personal use only.

dovepress
50. corcostegui r, labeaga l, innerarity a, berisa a, orjales a. in vivo
pharmacological characterisation of  xxxd338xxx , a potent and selective
 xxxg1078xxx  antagonist. drugs r d. 2006;7:219‚Äì231.
51. jauregizar n, de la fuente l, lucero ml, sologuren a, leal n,
rodr√≠guez m. pharmacokinetic-pharmacodynamic modelling of the
antihistaminic (h1) effect of  xxxd338xxx . clin pharmacokinet. 2009;48:
543‚Äì554.
52. sadaba b, gomez-guiu a, azanza jr, ortega i, valiente r. oral availability of  xxxd338xxx . clin drug investig. 2013;33:375‚Äì381.
53. lucero ml, gonzalo a, mumford r, betanzos m, alejandro a. an
overview of  xxxd338xxx  metabolism during preclinical investigations.
drug chem toxicol. 2012;35(suppl 1):18‚Äì24.
54. lasseter kc, sologuren a, la noce a, dilzer sc. evaluation of the
single-dose pharmacokinetics of  xxxd338xxx  in subjects with various
degrees of renal insufficiency. clin drug investig. 2013;33:665‚Äì673.
55. lucero ml, gonzalo a, ganza a, et al. interactions of  xxxd338xxx , a new
oral h(1) antihistamine, with human transporter systems. drug chem
toxicol. 2012;35(suppl 1):8‚Äì17.
56. horak f, zieglmayer p, zieglmayer r, lemell p. the effects of  xxxd338xxx  compared with cetirizine, fexofenadine, and placebo on allergeninduced nasal and ocular symptoms in patients exposed to aeroallergen
in the vienna challenge chamber. inflamm res. 2010;59:391‚Äì398.
57. kuna p, bachert c, nowacki z, et al;  xxxd338xxx  international working
group. efficacy and safety of  xxxd338xxx  20 mg compared with cetirizine
10 mg and placebo for the symptomatic treatment of seasonal allergic
rhinitis: a randomized, double-blind, parallel-group study. clin exp
allergy. 2009;39:1338‚Äì1347.
58. bachert c, kuna p, sanquer f, et al;  xxxd338xxx  international working group.
comparison of the efficacy and safety of  xxxd338xxx  20 mg vs  xxxd1846xxx 
5 mg in seasonal allergic rhinitis patients. allergy. 2009;64:158‚Äì165.
59. bartra j, mullol j, montoro j, et al. effect of  xxxd338xxx  upon the ocular
symptoms of allergic rhinoconjunctivitis. j investig allergol clin
immunol. 2011;21(suppl 3):24‚Äì33.
60. sastre j, mullol j, valero a;  xxxd338xxx  study group. efficacy and safety
of  xxxd338xxx  20 mg compared with cetirizine 10 mg and placebo in the
treatment of perennial allergic rhinitis. curr med res opin. 2012;28:
121‚Äì130.
61. zuberbier t, oanta a, bogacka e, et al;  xxxd338xxx  international working group. comparison of the efficacy and safety of  xxxd338xxx  20 mg
vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria:
a multi-centre, double-blind, randomized, placebo-controlled study.
allergy. 2010;65:516‚Äì528.
62. church mk. comparative inhibition by  xxxd338xxx  and cetirizine of
histamine-induced wheal and flare responses in humans. inflamm res.
2011;60:1107‚Äì1112.
63. kulthanan k, jiamton s, thumpimukvatana n, pinkaew s. chronic idiopathic urticaria: prevalence and clinical course. j dermatol. 2007;34:
294‚Äì301.

 xxxd338xxx  in allergic rhinitis and urticaria
64. krause k, spohr a, zuberbier t, church mk, maurer m. up-dosing
with  xxxd338xxx  results in improved effectiveness in cold contact urticaria.
allergy. 2013;68:921‚Äì928.
65. garcia-gea c, martinez j, ballester mr, gich i, valiente r,
antonijoan rm. psychomotor and subjective effects of  xxxd338xxx ,
hydroxyzine, and cetirizine, in combination with alcohol: a randomized,
double-blind, crossover, and positive-controlled and placebo-controlled
phase i clinical trials. hum psychopharmacol. 2014;29:120‚Äì132.
66. conen s, theunissen el, van oers ac, valiente r, ramaekers jg.
acute and subchronic effects of  xxxd338xxx  (20 and 40 mg) and hydroxyzine
(50 mg) on actual driving performance in healthy volunteers.
j psychopharmacol. 2011;25:1517‚Äì1523.
67. farre m, perez-mana c, papaseit e, et al.  xxxd338xxx  vs. hydroxyzine:
occupation of brain histamine h1 ‚Äì receptors evaluated by positron
emission tomography in healthy volunteers. br j clin pharmacol.
2014;78:970‚Äì980.
68. jauregui i, ramaekers jg, yanai k, et al.  xxxd338xxx : a new antihistamine
with an optimal benefit-to-risk ratio for safety during driving. expert
opin drug saf. 2016;15(1):89‚Äì98.
69. yanai k, ryu jh, watanabe t, et al.  xxxg1078xxx  occupancy
in human brains after single oral doses of histamine h1 antagonists measured by positron emission tomography. br j pharmacol.
1995;116:1649‚Äì1655.
70. yanai k, okamura n, tagawa m, itoh m, watanabe t. new findings in
pharmacological effects induced by antihistamines: from pet studies
to knock-out mice. clin exp allergy. 1999;29(suppl 3):29‚Äì36.
71. okamura n, yanai k, higuchi m, et al. functional neuroimaging of
cognition impaired by a classical antihistamine, d-chlorpheniramine.
br j pharmacol. 2000;129:115‚Äì123.
72. tagawa m, kano m, okamura n, et al. neuroimaging of histamine
h1-receptor occupancy in human brain by positron emission tomography (pet): a comparative study of ebastine, a second-generation
antihistamine and (+)-chlorpheniramine, a classical antihistamine.
br j clin pharmacol. 2001;52:501‚Äì509.
73. tashiro m, sakurada y, iwabuchi k, et al. central effects of fexofenadine and cetirizine: measurement of psychomotor performance,
subjective sleepiness, and brain histamine h1-receptor occupancy
using 11c-doxepin positron emission tomography. j clin pharmacol.
2004;44:890‚Äì900.
74. graff c, struijk jj, kanters jk, andersen mp, toft e, tyl b. effects
of  xxxd338xxx  on t-wave morphology and the qtc interval: a randomized, double-blind, placebo-controlled, thorough qtc study. clin drug
investig. 2012;32:339‚Äì351.
75. prepageran n, wang de y, nair g, maurer m. the status quo and unmet
needs in the management of allergic rhinitis and chronic rhinosinusitis:
a malaysian perspective. asia pac allergy. 2014;4:142‚Äì148.

dovepress

therapeutics and clinical risk management

publish your work in this journal
therapeutics and clinical risk management is an international, peerreviewed journal of clinical therapeutics and risk management, focusing
on concise rapid reporting of clinical studies in all therapeutic areas,
outcomes, safety, and programs for the effective, safe, and sustained
use of medicines. this journal is indexed on pubmed central, cas,

embase, scopus and the elsevier bibliographic databases. the
manuscript management system is completely online and includes a
very quick and fair peer-review system, which is all easy to use. visit
http://www.dovepress.com/testimonials.php to read real quotes from
published authors.

submit your manuscript here: http://www.dovepress.com/therapeutics-and-clinical-risk-management-journal

therapeutics and clinical risk management 2016:12

submit your manuscript | www.dovepress.com

dovepress

powered by tcpdf (www.tcpdf.org)

597

